Marc Goodman
Stock Analyst at Leerink Partners
Total Price Targets
9
Stocks Covered
6
Sectors
Healthcare
Most Recent
Mar 3, 2026
Notable Calls (Last 12 Months)
Stocks Covered by Marc Goodman
| Symbol | Company | Latest Target | Current Price | Upside | # Targets | Last Updated |
|---|---|---|---|---|---|---|
| BHVN | Biohaven Ltd. | $15.00 | $13.46 | +11.4% | 2 | Mar 3, 2026 |
| NMRA | Neumora Therapeutics, Inc. Common Stock | $8.00 | $1.60 | +398.4% | 1 | Jan 12, 2026 |
| AMLX | Amylyx Pharmaceuticals, Inc. | $10.00 | $20.36 | -50.9% | 2 | May 6, 2025 |
| STOK | Stoke Therapeutics, Inc. | $18.00 | $28.89 | -37.7% | 1 | Oct 11, 2024 |
| NBIX | Neurocrine Biosciences, Inc. | $115.00 | $167.32 | -31.3% | 2 | Nov 2, 2022 |
| ACAD | ACADIA Pharmaceuticals Inc. | $31.00 | $25.77 | +20.3% | 1 | Feb 28, 2022 |
Recent Activity
- Mar 3, 2026— Set$15.00price target onBHVN(Biohaven Ltd.)
- Jan 12, 2026— Set$8.00price target onNMRA(Neumora Therapeutics, Inc. Common Stock)
- May 6, 2025— Set$10.00price target onAMLX(Amylyx Pharmaceuticals, Inc.)
- Oct 18, 2024— Set$4.00price target onAMLX(Amylyx Pharmaceuticals, Inc.)
- Oct 11, 2024— Set$18.00price target onSTOK(Stoke Therapeutics, Inc.)
- Sep 24, 2024— Set$60.00price target onBHVN(Biohaven Ltd.)
- Nov 2, 2022— Set$115.00price target onNBIX(Neurocrine Biosciences, Inc.)
- Feb 28, 2022— Set$31.00price target onACAD(ACADIA Pharmaceuticals Inc.)
- Feb 11, 2022— Set$100.00price target onNBIX(Neurocrine Biosciences, Inc.)
Frequently Asked Questions
Who is Marc Goodman?
Marc Goodman is a stock analyst at Leerink Partners covering 6 stocks primarily in Healthcare. They have issued 9 price targets since Feb 11, 2022.
What stocks does Marc Goodman cover?
Marc Goodman currently covers 6 stocks, including BHVN, AMLX, NBIX, NMRA, STOK.
What is Marc Goodman's latest price target?
Marc Goodman's most recent price target was $15.00 on BHVN (Biohaven Ltd.), set on Mar 3, 2026.
What is Marc Goodman's highest price target?
Marc Goodman's highest issued price target is $115.00 on NBIX, set on Nov 2, 2022.
More Analysts at Leerink Partners
Coverage based on publicly published price targets. Not investment advice.